Breadcrumb AMCP.org Corporate Opportunities National Meetings Calendar TRODELVY® (sacituzumab govitecan-hziy): A Drug Investigated for Treatment of HR+/HER2- Metastatic Breast Cancer TRODELVY® (sacituzumab govitecan-hziy): A Drug Investigated for Treatment of HR+/HER2- Metastatic Breast Cancer Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page Date: Wednesday, February 1, 2023, 2–3 pm ETEvent Type: WebinarsPrice: Member: Free Non-Member: FreeRegister Today